CAJ | 학술논문

目的：系统评价肝移植受者使用他克莫司缓释剂型与普通剂型的有效性与安全性。方法检索Pubmed、CNKI等中英文数据库，对肝移植术后使用这2种剂型的随机对照试验（RCT）进行收集，用Revman 5.2软件对纳入研究的数据进行Meta分析。结果共纳入4项RCTs，含797例成年肝移植受者。他克莫司缓释剂型与普通剂型相比，有效性及安全性比较差异均无统计学意义，但缓释剂型组的高血糖发生率显著低于普通剂型组（ P＜0.05）。结论在肝移植受者中，2种剂型有同等的有效性及安全性，但是缓释剂型组的高血糖发生率较低。
목적：계통평개간이식수자사용타극막사완석제형여보통제형적유효성여안전성。방법검색Pubmed、CNKI등중영문수거고，대간이식술후사용저2충제형적수궤대조시험（RCT）진행수집，용Revman 5.2연건대납입연구적수거진행Meta분석。결과공납입4항RCTs，함797례성년간이식수자。타극막사완석제형여보통제형상비，유효성급안전성비교차이균무통계학의의，단완석제형조적고혈당발생솔현저저우보통제형조（ P＜0.05）。결론재간이식수자중，2충제형유동등적유효성급안전성，단시완석제형조적고혈당발생솔교저。
Objective To systematically assess the efficacy and safety of extended-release versus standard -release tacrolimus in liver transplant recipients.Methods Searched Pubmed , CNKI and other databases in both English and Chinese , researched published randomized controlled trials( RCT) focused on extended -release versus standard -release ta-crolimus in the liver transplant recipients.Meta-analysis was conducted by Revman 5.2 software.Results A total of 4 RCTs were included ,in-volving 797 adult liver transplant recipients.The results of Meta-analy-sis revealed that:no significant differences between the extended -release group and the standard -release group in both efficacy and safety was shown.But the incidence of hyperglycemia in the extended -release group was significantly lower than that of the standard -release group ( P<0.05 ).Conclusion Compared to the standard -release tacroli-musinthelivertransplant recipients , extended -release tacrolimus are e-qually effective for preventing and treating the acute rejection and impro-ving outcomes .And they are almost equally safe except the lower inci-dence of hyperglycemia for the extended -release tacrolimus.